EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-AS-01(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for AS is strictly investigational and experimental. It is not an approved routine commercial cure and cannot reverse fused vertebrae ("bamboo spine") or replace standard rheumatologic disease-modifying therapies.
Pathophysiology & Disease Context:
Ankylosing Spondylitis (AS) is a chronic, immune-mediated inflammatory arthritis primarily targeting the sacroiliac joints and axial skeleton, driven by HLA-B27 associations, Th17/Treg dysregulation, and excess TNF-$\alpha$ and IL-17/23 signaling.
Biological Rationale & Paracrine Action:
Investigates the immunomodulatory paracrine potential of clinical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs) or autologous bone marrow mononuclear cells (BMMNCs) to reset the Th17/Treg balance, inhibit osteoclastogenesis, and suppress systemic spinal inflammation.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Adults with clinically confirmed active axial spondyloarthritis or AS (modified New York criteria) who have shown inadequate response or intolerance to at least two NSAIDs and conventional/biologic DMARDs.
Mandatory Pre-Procedure Diagnostics:
Pelvis & spine MRI (evaluating active sacroiliac bone marrow edema), baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI $\ge 4$), acute phase reactants (hs-CRP, ESR), HLA-B27 status, and chest X-ray/TB QuantiFERON gold screen.
Strict Safety Exclusion Parameters:
Complete bony ankylosis with total loss of spinal mobility (non-inflammatory stage), active systemic bacterial/tubercular infections, active malignancy, or severe cardiovascular/renal failure.
Triage Protocol & Multi-Specialty Clearance:
Joint evaluation by a rheumatology and orthopedic board prior to issuing medical visa clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Inflammation Reduction: Decreases in elevated C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) levels.
- Pain & Stiffness Relief: Meaningful reductions in subjective BASDAI scores and morning spinal stiffness duration.
- Spinal Flexibility: Modest improvements in the Bath Ankylosing Spondylitis Metrology Index (BASMI), such as thoracic expansion and lumbar flexion.
- Decreased NSAID Reliance: Potential reduction in daily painkiller or corticosteroid dosage under medical supervision.
Documented Procedural Risks & Limits:
- Transient post-infusion low-grade fever, chills, or headache resolving spontaneously within 24–48 hours.
- Temporary injection-site tenderness or bruising (with localized delivery).
- No Guaranteed Structural Reversal: Cellular therapy does not dissolve syndesmophytes, reverse structural joint fusion, or ensure permanent biological remission.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Hospitals
Delivered exclusively within tertiary medical campuses accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH) and JCI.
Rheumatology Board Oversight
Collaborative care led by board-certified clinical rheumatologists, spine specialists, and cellular immunologists.
cGMP Cleanroom Rigor
Cell processing complies fully with CDSCO quality control standards and international Good Manufacturing Practices.
Transparent Ethics Oversight
Regulated by an active Institutional Ethics Committee (IEC) registered with the Department of Health Research (DHR).
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Detailed telemedicine session with lead rheumatologists to review spinal imaging, inflammatory markers, and travel fitness.
Government Medical Visa
Fast-track assistance with official Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation letters.
Dedicated Case Liaison
Single multilingual point of contact managing airport coordination, daily clinic schedules, and document translation.
Remote Follow-Up Program
Telehealth reviews at Months 1, 3, 6, and 12, sharing inflammatory blood markers and BASDAI scores directly with your home rheumatologist.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Safe Airport Transfers
Private, air-conditioned vehicle pick-up and drop-off to avoid jarring transit for patients with spinal sensitivity.
Orthopedic Accommodations
Hospital suites and partner serviced apartments equipped with firm orthopedic mattresses, accessible walk-in showers, and elevator access within 10 minutes of the center.
Patient Amenities
Anti-inflammatory dietary planning supervised by clinical nutritionists, local SIM card registration, and 24/7 nursing access.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 5 days structured in-hospital observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Ankylosing Spondylitis
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Prospective Clinical Trial on Intravenous Allogeneic Bone Marrow MSCs in Active AS
Wang, P., Li, Y., Huang, L., Yang, J., Yang, R., Deng, W., Liang, B., Dai, L., Meng, Q., Gao, L., Chen, X., Shen, J., Tang, Y., Zhang, X., Hou, J., Ye, J., Chen, K., Cai, Z., Wu, Y., & Shen, H. (2014). Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial. Cell Transplantation, 23(10), 1293–1303.
Clinical Cohort on Intravenous Umbilical Cord-Derived MSCs in Ankylosing Spondylitis
Li, A., Ni, X., Deng, W., et al. (2017). Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis. Experimental and Therapeutic Medicine, 14(2), 1538–1546.
In Vitro Immunoregulatory Profiling of Adipose-Derived MSCs in AS Patients
Kuca-Warnawin, E., Janicka, I., Szczęsny, P., Olesińska, M., Bonek, K., Głuszko, P., & Kontny, E. (2021). Inhibition of Allogeneic and Autologous T Cell Proliferation by Adipose-Derived Mesenchymal Stem Cells of Ankylosing Spondylitis Patients. Stem Cells International, 2021, 6637328.
Systematic Review & Meta-Analysis of MSC Therapy in Autoimmune Rheumatic Diseases
Sun, Y., Deng, W., & Zhang, H. et al. (2022). Efficacy and Safety of Mesenchymal Stem Cell Transplantation in the Treatment of Autoimmune Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Stem Cells International, 2022, 4363540.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), as well as directives from the National Medical Commission (NMC), stem cell therapy for Ankylosing Spondylitis is classified as investigational and experimental. It is not recognized by the Central Drugs Standard Control Organisation (CDSCO) as an approved standard commercial treatment or cure. It must be administered strictly within ethics-committee-approved clinical research protocols. Patients are strongly advised never to stop or alter their prescribed biologics, DMARDs, or daily posture/stretching exercises without direct rheumatologist consultation.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.